The effect of coenzyme Q10 supplement on Prevention of hepatotoxicity in patients with major ß-thalassemia

The effect of coenzyme Q10 supplement on Prevention of hepatotoxicity Caused by iron-overload in patients with major ß-thalassemia referred to Hajar Hospital

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221211056777N2

Enrollment

Registered

2023-08-06

Start date

2023-03-02

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thalassemia. Beta thalassemia

Interventions

50 individuals with major thalassemia will be selected. Laboratory parameters (ALT, AST, HB, Ferritin, ESR, CRP, TIBC, LDH) will be examined initially and recorded along with demographic information i

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with thalassemia major Patients with thalassemia major with elevated liver enzymes Patients with thalassemia major with elevated inflammation markers

Exclusion criteria

Exclusion criteria: Patients with active viral hepatitis Hepatotoxic drugs consumption Hypersplenism

Design outcomes

Primary

Measure	Time frame
Level of aspartate aminotransferase (AST) in blood. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Level of alanine transaminase (ALT) in blood. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Level of hemoglobin (Hb) in blood. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Level of ferritin in blood. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Measuring erythrocyte sedimentation rate (ESR). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Level of C-reactive protein (Crp) in blood. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Measuring Total iron binding capacity (TIBC). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Level of lactate dehydrogenase (LDH) in blood. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.	—

Measure

Time frame

Level of aspartate aminotransferase (AST) in blood. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Level of alanine transaminase (ALT) in blood. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Level of hemoglobin (Hb) in blood. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Level of ferritin in blood. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Measuring erythrocyte sedimentation rate (ESR). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Level of C-reactive protein (Crp) in blood. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Measuring Total iron binding capacity (TIBC). Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.;Level of lactate dehydrogenase (LDH) in blood. Timepoint: Before the intervention and eight weeks after the intervention. Method of measurement: Biochemical laboratory kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMilad Nami

Shahre-kord University of Medical Sciences

miladnami75@gmail.com+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026